Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Norketotifen by Emergo Therapeutics for Unspecified Influenza Virus Infections: Likelihood of Approval
Norketotifen is under clinical development by Emergo Therapeutics and currently in Phase II for Unspecified Influenza Virus Infections. According to...
Data Insights
Norketotifen by Emergo Therapeutics for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): Likelihood of Approval
Norketotifen is under clinical development by Emergo Therapeutics and currently in Phase I for Chronic Fatigue Syndrome (Myalgic Encephalomyelitis). According...